Rajaneesh K. Gopinath
WRITTEN BY Rajaneesh K. Gopinath
Merck Acquires Acceleron for $11.5 Billion, Gaining Access to a Phase 3 Cardiovascular Asset
2021-09-30
Bispecific Antibodies or CAR T-Cells: Which One of These Cancer Immunotherapies Would Prevail?
2021-09-29
Novartis Expands Optogenetics Portfolio By Acquiring Swiss Startup for an Undisclosed Amount
2021-09-21
Lilly, Innovent’s Tyvyt Registers Positive Outcomes in Esophageal and Gastric Cancer Trials
2021-09-17